Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

Autor: Heney, Niall M., Koontz, Warren W., Barton, Bruce, Soloway, Mark, Trump, Donald L., Hazra, Tapan, Weinstein, Ronald S.
Zdroj: The Journal of Urology; December 1988, Vol. 140 Issue: 6 p1390-1393, 4p
Abstrakt: A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder. Eight weekly instillations were given followed by cystoscopy 4 weeks after the treatment was stopped. The over-all complete response rate based on cystoscopy and either biopsy or cytology was 26 per cent for thiotepa versus 39 per cent for mitomycin C (p equals 0.08). The greatest efficacy was seen in the Ta group with mitomycin C demonstrating superiority over thiotepa.
Databáze: Supplemental Index